Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479000 | 0.91 | KDR (0.51) | KDRHRH4HPGDTSHRRIPK1 | |
| SCHEMBL6479001 | 0.89 | NPC1 (0.47) | KDRHRH4HRH3HPGDRIPK1 | |
| SCHEMBL5753668 | 0.86 | KDR (0.45) | KDRHRH4HRH3MGLL | |
| SCHEMBL6478882 | 0.83 | MAPK14 (0.62) | TSHRMGLLMEN1KMT2A | |
| SCHEMBL6490732 | 0.80 | CDK5 (0.48) | HRH3HPGDRIPK1MEN1KMT2A | |
| SCHEMBL5754444 | 0.78 | HRH3 (0.46) | HRH3HPGD | |
| SCHEMBL6480600 | 0.77 | CHEK1 (0.43) | HPGDMEN1KMT2A | |
| SCHEMBL13646754 | 0.77 | HRH4 (0.64) | KDRHRH4HRH3HRH1HPGD | |
| SCHEMBL5755806 | 0.77 | MMP2 (0.47) | RIPK1 | |
| SCHEMBL5754341 | 0.77 | HSP90AA1 (0.41) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K9, MAP3K20, MAP3K19 | KDR 1419/4885HRH4 3130/4885HRH3 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.